Patient-reported outcomes before treatment for localized prostate cancer: are there differences among countries? Data from the True North Global Registry

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Garin Boronat, Olatz, 1979-
• dc.contributor.author Zamora, Víctor
• dc.contributor.author Ferrer Forés, Maria Montserrat
• dc.contributor.author Pont Acuña, Àngels
• dc.contributor.author True North Global Registry
• dc.date.accessioned 2024-04-26T06:32:34Z
• dc.date.available 2024-04-26T06:32:34Z
• dc.date.issued 2023
• dc.description.abstract Introduction: Similar Patient-Reported Outcomes (PROs) at diagnosis for localized prostate cancer among countries may indicate that different treatments are recommended to the same profile of patients, regardless the context characteristics (health systems, medical schools, culture, preferences…). The aim of this study was to assess such comparison. Methods: We analyzed the EPIC-26 results before the primary treatment of men diagnosed of localized prostate cancer from January 2017 onwards (revised data available up to September 2019), from a multicenter prospective international cohort including seven regions: Australia/New Zealand, Canada, Central Europe (Austria / Czech Republic / Germany), United Kingdom, Italy, Spain, and the United States. The EPIC-26 domain scores and pattern of three selected items were compared across regions (with Central Europe as reference). All comparisons were made stratifying by treatment: radical prostatectomy, external radiotherapy, brachytherapy, and active surveillance. Results: The sample included a total of 13,483 men with clinically localized or locally advanced prostate cancer. PROs showed different domain patterns before treatment across countries. The sexual domain was the most impaired, and the one with the highest dispersion within countries and with the greatest medians' differences across countries. The urinary incontinence domain, together with the bowel and hormonal domains, presented the highest scores (better outcomes) for all treatment groups, and homogeneity across regions. Conclusions: Patients with localized or locally advanced prostate cancer undergoing radical prostatectomy, EBRT, brachytherapy, or active surveillance presented mainly negligible or small differences in the EPIC-26 domains before treatment across countries. The results on urinary incontinence or bowel domains, in which almost all patients presented the best possible score, may downplay the baseline data role for evaluating treatments' effects. However, the heterogeneity within countries and the magnitude of the differences found across countries in other domains, especially sexual, support the need of implementing the PRO measurement from diagnosis.
• dc.format.mimetype application/pdf
• dc.identifier.citation Garin O, Kowalski C, Zamora V, Roth R, Ferrer M, Breidenbach C, et al. Patient-reported outcomes before treatment for localized prostate cancer: are there differences among countries? Data from the True North Global Registry. BMC Urol. 2023 Nov 3;23(1):178. DOI: 10.1186/s12894-023-01344-0
• dc.identifier.doi http://dx.doi.org/10.1186/s12894-023-01344-0
• dc.identifier.issn 1471-2490
• dc.identifier.uri http://hdl.handle.net/10230/59908
• dc.language.iso eng
• dc.publisher BioMed Central
• dc.relation.ispartof BMC Urol. 2023 Nov 3;23(1):178
• dc.rights © The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword Health-related quality of life
• dc.subject.keyword Patient-reported outcomes
• dc.subject.keyword Prostate cancer
• dc.subject.keyword Registry
• dc.title Patient-reported outcomes before treatment for localized prostate cancer: are there differences among countries? Data from the True North Global Registry
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion